Kimberly-Clark Corporation is a global company specializing in the manufacturing and marketing of products made from natural or synthetic fibers and materials. The company operates through three main business segments, offering a variety of personal care, consumer tissue, and professional products. Kimberly-Clark's product portfolio includes well-known brands such as Huggies, Kleenex, and Scott, which hold leading positions in their respective markets .
- Personal Care - Manufactures and markets disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, and reusable underwear under brands like Huggies, Pull-Ups, Kotex, and Depend .
- Consumer Tissue - Offers facial and bathroom tissue, paper towels, and napkins under brands like Kleenex, Scott, and Cottonelle .
- K-C Professional - Provides wipers, tissue, towels, and personal protective equipment with brands including Kleenex, Scott, and WypAll .
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Michael D. Hsu ExecutiveBoard | Chairman of the Board and CEO | Board Member at McDonald's Corporation; Board Member at Texas Instruments | Joined KMB in 2012; became CEO in 2019 and Chairman in 2020; previously held leadership roles at Kraft Foods and Heinz. | View Report → |
Craig Slavtcheff Executive | Chief Research and Development Officer | None | Joined KMB in 2024; previously EVP and Chief R&D Officer at Campbell Soup Company. | |
Ehab Abou-Oaf Executive | President, International Family Care and Professional | Board Member at American University in Cairo; Board Member at Singapore American School | Joined KMB in 2020; previously held leadership roles at Mars, Inc. and Procter & Gamble. | |
Grant B. McGee Executive | Senior Vice President, General Counsel, and Corporate Secretary | None | Rejoined KMB in 2024; previously held legal leadership roles at American Airlines and KMB. | |
Jeffrey Melucci Executive | Chief Business, Strategy and Transformation Officer | None | Joined KMB in 2013; held various leadership roles, including Chief Business Development and Legal Officer. | |
Katy Chen Executive | President, International Personal Care | None | Joined KMB in 2009; previously led KMB's China operations and digital transformation initiatives. | |
Nelson Urdaneta Executive | Senior Vice President and CFO | None | Joined KMB in 2022; previously held senior finance roles at Mondelēz International and Ryder System, Inc. | |
Patricia Corsi Executive | Chief Growth Officer | None | Joined KMB in 2024; previously Chief Marketing, IT, and Digital Officer at Bayer Consumer Health. | |
Russell Torres Executive | President, North America | None | Joined KMB in 2020; previously held leadership roles at Newell Brands and Mondelēz International. | |
Sandra R.A. Karrmann Executive | Senior Vice President and Chief People Officer | None | Joined KMB in 2020; previously held HR leadership roles at Tenet Healthcare and United Surgical Partners International. | |
Tamera Fenske Executive | Senior Vice President and Chief Supply Chain Officer | None | Joined KMB in 2022; previously held senior supply chain roles at 3M Company. | |
Zackery Hicks Executive | Chief Digital and Technology Officer | Board Member at Signet Jewelers Ltd | Joined KMB in 2022; previously held digital leadership roles at Toyota Motor North America. | |
Christa S. Quarles Board | Director | CEO of Alludo; Board Member at Affirm Holdings, Inc. | Joined KMB's board in 2016; former CEO of OpenTable and leader in digital transformation. | |
Deeptha Khanna Board | Director | EVP and Chief Business Leader, Personal Health at Royal Philips | Joined KMB's board in 2023; previously held leadership roles at Johnson & Johnson and Procter & Gamble. | |
Deirdre A. Mahlan Board | Director | Interim CEO and Chairperson of The Duckhorn Portfolio; Board Member at Haleon plc | Joined KMB's board in 2021; former President of Diageo North America and CFO of Diageo plc. | |
Dunia A. Shive Board | Director | Board Member at DallasNews Corporation, Main Street Capital Corporation, and Trinity Industries | Joined KMB's board in 2019; former CEO of Belo Corp. | |
Jaime A. Ramirez Board | Director | None | Joined KMB's board in 2021; former EVP and President, Global Tools & Storage at Stanley Black & Decker. | |
John W. Culver Board | Director | Board Member at Columbia Sportswear Company; Director at The Mission Continues | Joined KMB's board in 2020; former Group President at Starbucks Corporation. | |
Joseph Romanelli Board | Director | President of Human Health International at Merck & Co., Inc. | Joined KMB's board in 2024; former CEO of JiXing Pharmaceuticals and leader in global biopharmaceutical operations. | |
Mae C. Jemison Board | Director | Founder of The Jemison Group; Principal for the 100 Year Starship Project | Joined KMB's board in 2002; former NASA astronaut and leader in science and technology innovation. | |
Mark T. Smucker Board | Director | Chair of the Board, President, and CEO of The J.M. Smucker Company | Joined KMB's board in 2019; leads The J.M. Smucker Company and has extensive experience in branded consumer goods. | |
S. Todd Maclin Board | Director | Board Member at Trinity Industries; Board Advisor at Cyber Defense Labs | Joined KMB's board in 2019; retired after a 37-year career at JPMorgan Chase & Co. | |
Sherilyn S. McCoy Board | Director | Board Member at Stryker Corporation | Joined KMB's board in 2018; former CEO of Avon Products and Vice Chairman at Johnson & Johnson. | |
Sylvia M. Burwell Board | Director | President of American University; Board Member at GuideWell Mutual Holding Corporation | Joined KMB's board in 2022; former U.S. Secretary of Health and Human Services and Director of the White House Office of Management and Budget. |
-
"You've noted that the exit from private label businesses will create a headwind of about 2% in 2025 due to ceasing production for a large club private label diaper business in the U.S. ; with this significant impact on revenue, what specific strategies are you implementing to offset this loss and drive growth in your branded products?"
-
"Given that your gross margin has expanded year-to-date and is tracking ahead of pre-COVID levels , but you're facing soft organic sales and potential need to increase promotions due to consumer pressures, how sustainable are these margin levels, and what risks do you see to maintaining them in the coming quarters?"
-
"Despite implementing your new organizational structure as of October 1 , you expect category growth to decelerate to the lower end of your long-term range ; how will this restructuring help drive the intended growth, and what challenges do you anticipate in achieving your goals?"
-
"Amid significant organizational changes and market volatility, including demand deceleration in key regions and channels , how has your visibility into business performance and forecasting accuracy been affected, and what measures are you taking to improve it?"
-
"With innovations like Skin Essentials reportedly exhibiting high cannibalization rates , how do you assess the effectiveness of such products in driving net incremental growth versus merely shifting sales within your portfolio, and what strategies are in place to ensure innovation leads to market share gains?"
Research analysts who have asked questions during KIMBERLY CLARK earnings calls.
Lauren Lieberman
Barclays
6 questions for KMB
Anna Lizzul
Bank of America Corporation
5 questions for KMB
Nik Modi
RBC Capital Markets
5 questions for KMB
Bonnie Herzog
Goldman Sachs
4 questions for KMB
Javier Escalante Manzo
Evercore ISI
4 questions for KMB
Peter Grom
UBS Group
3 questions for KMB
Chris Carey
Wells Fargo Securities
2 questions for KMB
Christopher Carey
Wells Fargo & Company
2 questions for KMB
Dara Mohsenian
Morgan Stanley
2 questions for KMB
Kevin Grundy
BNP Paribas
1 question for KMB
Korinne Wolfmeyer
Piper Sandler & Co.
1 question for KMB
Michael Lavery
Piper Sandler & Co.
1 question for KMB
Robert Moskow
TD Cowen
1 question for KMB
Stephen Robert Powers
Deutsche Bank
1 question for KMB
Steve Powers
Deutsche Bank
1 question for KMB
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
Thinx Inc. | 2023 | Kimberly-Clark increased its ownership in Thinx Inc. by acquiring additional common securities for $48 million in cash during the first half of 2023, raising its stake to 70%; this acquisition, which followed the initial 2022 majority investment totaling $181 million, was executed as an equity transaction with consolidation under the Personal Care segment. |
Recent press releases and 8-K filings for KMB.
- Absatz von 3,6 Mio. Tonnen Zellstoff und Papier, ein Anstieg um 20 % gegenüber 3Q24
- Zahlungsmittelkosten der Zellstoffproduktion gesunken auf 801 BRL je Tonne (− 7 % vs. 3Q24)
- Nettoumsatz von 12,2 Mrd. BRL, bereinigtes EBITDA 5,2 Mrd. BRL, operativer Mittelzufluss 3,4 Mrd. BRL und Nettogewinn 2 Mrd. BRL
- Suzano Packaging erzielte das erste positive bereinigte EBITDA aus den im Oktober 2024 erworbenen US-Aktivitäten
- Netto-Verschuldung im USD-Bereich bei 3,3-facher EBITDA; Barmittelbestand 6,5 Mrd. USD
- Shipments of pulp and paper rose 20% YoY to 3.6 million tonnes in Q3 2025.
- Production cash costs fell 7% YoY to 801 BRL/tonne, driven by the new Ribas do Rio Pardo mill.
- Net revenue was 12.2 billion BRL, adjusted EBITDA 5.2 billion BRL, operating cash flow 3.4 billion BRL, and net income 2 billion BRL.
- Net leverage ended at 3.3x in USD, with cash of 6.5 billion USD at quarter-end.
- Suzano Packaging’s U.S. operations recorded their first positive adjusted EBITDA since acquisition.
- Sales rose 20% Y-o-Y to 3.6 million tonnes of pulp and paper, driven by the new Ribas do Rio Pardo mill and US asset integration.
- Cash cost of pulp production fell 7% versus Q3 2024 to R$801/tonne.
- Net revenue was R$12.2 billion (flat Y-o-Y); Adjusted EBITDA reached R$5.2 billion, with operating cash flow of R$3.4 billion and net profit of R$2 billion.
- Net leverage stood at 3.3× in USD and the cash position was US$6.5 billion at quarter-end.
- Suzano Packaging’s US operations, acquired in October 2024, delivered their first positive Adjusted EBITDA.
- Brodsky & Smith is probing whether Kenvue’s board breached fiduciary duties in the $21.01 per share acquisition by Kimberly-Clark (comprised of $3.50 cash and 0.14625 KMB shares).
- The firm is also investigating Sonida Senior Living’s $6.90-per-share merger with CNL Healthcare Properties, structured as 66% stock and 34% cash.
- Evoke Pharma’s $11.00-per-share cash sale to QOL Medical is under scrutiny for fair process.
- SM Energy’s merger into Civitas Resources—featuring a 1.45 share exchange ratio and an implied $12.8 billion enterprise value—is likewise being reviewed.
- Kimberly-Clark will acquire Kenvue, the largest pure-play consumer health company by revenue, to create a leading global health & wellness firm.
- The transaction values Kenvue at $48.7 billion enterprise value, with shareholders receiving $21.01 per share ( $3.50 cash + 0.14625 K-C shares ).
- Pro forma ownership will be ~54% for current Kimberly-Clark shareholders and ~46% for Kenvue shareholders.
- The deal is expected to generate ~$2.1 billion in synergies ( $1.9 billion cost synergies and $0.2 billion margin flow-through ).
- Closing is targeted in the second half of 2026, supported by fully committed financing and a goal of ~2.0× net leverage within 24 months post-close.
- Kimberly-Clark will acquire Kinview in an all-stock transaction, forming a $32 billion net revenue company with $7 billion in EBITDA pre-synergies.
- The deal is expected to yield $2.1 billion in net EBITDA synergies over 3–4 years, driven by combined cost and revenue efficiencies.
- Financing via stock issuance and $1.8 billion Susano JV proceeds will lead to pro forma leverage of approximately 2x EBITDA within 24 months; guidance suggests mid-single-digit EPS dilution in year one, turning accretive in year two.
- The combined entity will manage 10 billion-dollar brands in OTC, skin care, oral care, and wound care, leveraging Kimberly-Clark’s innovation and commercial capabilities to tap into the $800 billion health and wellness market.
- Kimberly-Clark will acquire Kenvue in a cash-and-stock transaction valuing Kenvue at $48.7 billion enterprise value, creating a combined company with pro forma $32 billion revenue and $7 billion adjusted EBITDA in 2025; the deal is expected to close in 2H 2026.
- Kenvue shareholders will receive $3.50 in cash plus 0.14625 Kimberly-Clark shares per Kenvue share (total $21.01 per share), resulting in 46% ownership for Kenvue investors and 54% for existing Kimberly-Clark shareholders on a fully diluted basis.
- The acquisition is priced at 14.3× Kenvue’s LTM adjusted EBITDA (effective 8.8× including $2.1 billion of net run-rate synergies) and is expected to be accretive to Kimberly-Clark’s adjusted EPS by year 2.
- Anticipated synergies include $1.9 billion of cost savings and $0.5 billion of revenue synergies (offset by $0.3 billion of reinvestment), with $2.5 billion of cash costs to achieve them; financing will use cash on hand, new debt and proceeds from the 51% sale of the IFP business.
- Kimberly-Clark to acquire Kenvue in a cash-and-stock deal valued at $40 billion–$48.7 billion, offering $3.50 in cash plus 0.14625 KMB shares per Kenvue share (total $21.01)
- Deal will integrate Kenvue’s consumer health brands, including Tylenol, to expand Kimberly-Clark’s market position and product offerings
- Cash portion financed through cash reserves, new debt issuance, and proceeds from sale of a 51% stake in its International Family Care and Professional business
- Kenvue shares rose over 18% premarket, while Kimberly-Clark shares fell more than 13% post-announcement
- Kimberly-Clark will acquire all outstanding shares of Kenvue in a cash-and-stock deal valuing Kenvue at $48.7 billion enterprise value; the transaction is expected to close in H2 2026
- Kenvue shareholders will receive $3.50 per share in cash plus 0.14625 Kimberly-Clark shares, totaling $21.01 per share; pro forma ownership will be 54% Kimberly-Clark and 46% Kenvue
- The combined company is projected to generate $32 billion in 2025 net revenues and $7 billion of adjusted EBITDA, and realize $2.1 billion in run-rate synergies by year 2
- Mike Hsu will serve as Chairman and CEO of the combined company; the headquarters will remain in Irving, Texas, and three Kenvue directors will join Kimberly-Clark’s board
- Kimberly-Clark gained 10 bps market share in U.S. diapers in Q3 and 90 bps year-to-date, shifting promotional spend into Q4 to drive trial of new innovations (e.g., Blowout Blocker, HugFit 360) while promotional levels remain below 2019 norms; club channel growth and premiumization support positive volume-mix trends.
- Full-year organic sales are tracking 1.6% growth against category growth of ~2%, with Q4 expected to at least match Q3’s momentum, keeping full-year volume growth in line with categories.
- Gross tariffs have declined from ~$170 million to ~$100 million, with ~$50 million in mitigating actions still phasing in and full mitigation expected by early 2026.
- The planned mid-2026 closing of the IFB divestiture will boost equity-income by ~30% and support share repurchases—lifting continuing EPS growth—while total-company EPS will see near-term dilution as discontinued-ops income phases out.
- Long-term targets remain: ≥40% gross margin and 18–20% operating margin by decade-end, underpinned by integrated margin management and stabilized fiber costs through the Suzano JV.